Skip to main content

JHOP - March 2023 Vol 13 Special Feature

DOWNLOAD EDITORIAL PDF

Download Hopa Abstracts PDF

Editorial
HOPA Abstracts
Editorial
Editorial
Keeping the HOP(A) Live—Annual Conference Research Highlights
By Mark L. Zangardi, PharmD, MS, BCOP; Sara Kim, PharmD, BCOP
Read More
HOPA Abstracts
HOPA Abstracts, Tyrosine Kinase Inhibitor
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
Abstract #CR05
Read More
HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
Abstract #CR06
Read More
HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
Abstract #CR07
Read More
HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
Abstract #CR08
Read More
HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
Abstract #CR09
Read More
HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
Abstract #CR10
Read More
HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
Abstract #CR11
Read More
HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
Abstract #CR12
Read More
HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
Abstract #CR13
Read More
HOPA Abstracts, Venetoclax
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
Abstract #CR14
Read More
HOPA Abstracts
Safety Outcomes of Oxaliplatin Rapid-Rate Infusion versus Standard-Rate Infusion
Abstract #CR15
Read More
HOPA Abstracts
Strategies for Implementing an Oral Medication Adherence Intervention
Abstract #CR16
Read More
HOPA Abstracts
Effectiveness of High-Dose Intravenous Acyclovir in Preventing Cytomegalovirus Infection in Allogeneic Stem-Cell Transplantation Recipients: A Retrospective Study in a Medical Center in Singapore
Abstract #CR17
Read More
HOPA Abstracts
Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with Extensive-Stage Small-Cell Lung Cancer in US Community Oncology Settings
Abstract #CR18
Read More
HOPA Abstracts
Urinary Tract Infections in Patients Receiving Chemotherapy and SGLT2 Inhibitors
Abstract #CR19
Read More
HOPA Abstracts
Use of Ursodiol for SOS/VOD Prophylaxis in Patients with Acute Leukemia Receiving Gemtuzumab-Ozogamicin or Inotuzumab-Ozogamicin
Abstract #CR20
Read More
HOPA Abstracts
Use of Bevacizumab Originator versus Biosimilar Drugs for Oncology Indications in a Real-World Data Sample
Abstract #CR21
Read More
HOPA Abstracts, Tyrosine Kinase Inhibitor
Veterans Health Administration Pharmacy Benefits Management Anti-Cancer Stewardship Pilot: Why Switch to a Second-Line Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia?
Abstract #CR22
Read More
HOPA Abstracts
Assessment and Education of Biosimilars Across an Outpatient Oncology Infusion Network
Abstract #CR23
Read More
HOPA Abstracts
Optimizing Corticosteroid Use for Immune-Related Adverse Events at a Community Oncology Practice
Abstract #LB01
Read More
HOPA Abstracts
Efficacy of Tixagevimab-Cilgavimab in Preventing SARS-CoV-2 in Patients with Hematologic Malignancies
Abstract #LB02
Read More
HOPA Abstracts
Potentially Inappropriate Medication Use and Cognition in Older Women with Breast Cancer
Abstract #LB03
Read More
HOPA Abstracts
Safety and Tolerability of an Alternative Capecitabine Dosing Schedule in Patients with Colorectal Cancer
Abstract #LB04
Read More
HOPA Abstracts
Biosimilar Uptake and Cost-Savings Analysis Before and After the Implementation of a Pharmacist-Driven Substitution Program Within a National Community Oncology Network
Abstract #CR02
Read More
HOPA Abstracts, Tyrosine Kinase Inhibitor
Bruton Tyrosine Kinase Inhibitors: Real-World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital
Abstract #CR03
Read More
HOPA Abstracts
Clinical Outcomes in Patients with Tumor PD-L1 Less Than 1% Who Received First-Line Nivolumab plus Ipilimumab and 2 Cycles of Chemotherapy versus Chemotherapy Alone for Metastatic NSCLC: Results from CheckMate 9LA
Abstract #CR04
Read More